Co-delivery of siRNA and doxorubicin to cancer cells from additively manufactured implants

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


  • Muwan Chen
  • Morten Østergaard Andersen, University of Southern Denmark, Interdisciplinary Nanoscience Center, Aarhus University, Orthopaedic Research Laboratory, Aarhus University Hospital, Department of Molecular Biology and Genetics - Aarhus University, Denmark
  • Philipp Dillschneider, Denmark
  • Chi-Chih (Clare) Chang, Denmark
  • Shan Gao, Denmark
  • Dang Quang Svend Le
  • Chuanxu Yang, Denmark
  • San Hein, Denmark
  • Cody Bünger
  • Jørgen Kjems
Tumors in load bearing bone tissue are a major clinical problem, in part because surgical resection invokes a dilemma whether to resect aggressively, risking mechanical failure, or to resect conservatively, risking cancer recurrence due to residual malignant cells. A chemo-functionalized implant, capable of physically supporting the void while killing residual cancer cells, would be an attractive solution. Here we describe a novel additively manufactured implant that can be functionalized with chitosan/siRNA nanoparticles. These induce long term gene silencing in adjacent cancer cells without showing toxicity to normal cells. When scaffolds are functionalized with siRNA/chitosan nanoparticles and doxorubicin in combination, their effects synergized leading to cancer cell death. This technology may be used to target resistance genes by RNA interference and thereby re-sensitizing the cancer cells to co-delivered chemotherapy.
Original languageEnglish
JournalRSC Advances
Pages (from-to)101718-101725
Number of pages8
Publication statusPublished - 16 Nov 2015

See relations at Aarhus University Citationformats

ID: 95965154